Emergent BioSolutions Inc EBS.N, EBS is expected to show a fall in quarterly revenue when it reports results on August 6 for the period ending June 30 2025
The Gaithersburg Maryland-based company is expected to report a 42.5% decrease in revenue to $146.367 million from $254.7 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on May 7 2025, for the period ended June 30, was for revenue between $95.00 million and $120.00 million. (Sales/Revenue majority basis is on Total Revenue.)
LSEG's mean analyst estimate for Emergent BioSolutions Inc is for a loss of 49 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50, about 55.9% above its last closing price of $5.95
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | 0.46 | 0.44 | 0.71 | Beat | 61.4 |
Dec. 31 2025 | -0.50 | -0.49 | 0.05 | Beat | 110.1 |
Sep. 30 2024 | 0.13 | 0.14 | 1.37 | Beat | 878.6 |
Jun. 30 2024 | -0.94 | -0.94 | -2.32 | Missed | -145.5 |
Mar. 31 2024 | -0.87 | -0.86 | 0.59 | Beat | 168.6 |
Dec. 31 2023 | -0.14 | -0.19 | -0.77 | Missed | -305.3 |
Sep. 30 2023 | -0.25 | -0.22 | -0.48 | Missed | -114.9 |
Jun. 30 2023 | -0.53 | -0.49 | -1.06 | Missed | -117.8 |
This summary was machine generated August 4 at 22:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)